Yasho Industries

Posting the Q3 Concall Notes -

  1. EBITDA Margins stood at 19.5% and PAT margins at 10%
  2. Increase in volume @ 21% YoY and 5% for Nine months (Signaling Demand recovery)
  3. Dahej Plant’s Trail run has began and since the EBITDA margins of the products from new plant is 20%+ new leg of margin expansion will come from here
  4. Industrial segment accounted for more than 87% of the revenue out of which export accounted for 62% total revenue
  5. Incorporated subsidiary in US making it area for future growth
  6. Downward revision in the guidence of total plant capacity → Pakhajan can do 550 to 600 crores of revenue and Vapi can do 650 Crores (earlier guided for 700 to 750) at optimum utilisation (90%)
    this downward revision is just on account of correction in RM prices
  7. The prices of RM are correcting i.e. Inching Upward, but not at the speed it dropped
  8. The company is seeing spark already but too early to comment weather this will be fire or fizzle down
  9. current capacity is utilization 85%
  10. Will complete trial, will take govt approvals and then only can start taking orders as client will need everything before placing orders. Will get govt certification within 4 - 8 Weeks
  11. Peak EBITDA will be 120 crores from Vapi facility
  12. Depreciation is on lower side as some asset have got fully depreciated
  13. Peak debt will be 500 crores including WC
  14. Markets will rebound overall within next 2 quarters as the demand comes back in European as well as Asian country
  15. Vapi is completely saturated @18% EBITDA margins any new improvement will come from pakhajan only

Disclaimer as above

3 Likes

Hi @Ashar_Mann
From whatever I understood abt Yasho, is that the pricing of the items would be generally a pass through. if that is the case and the RM costs is inching upwards, then why would the revenue from the new plants decline, shouldn’t it increase? Did the mgmt say anything about why the downward revision to the revenue potential

Disclosure: not invested

1 Like

Hey @divygupta
So Yes you are correct that any kind of RM Increase will result in the increase in the revenue as the it’s a pass Through
The Downward Revision is on the basis of Current Prices of RM if you see management has said that they are not committing to the statement that Price will go back to mean of RM and hence the statement that → weather the price inching up is likely to be a fire or Fizzle out
Hence in short downward revision is Excluding the increasing RM Prices
→ my bad should have framed sentence better :sweat_smile:
Disclaimer as Above

1 Like

A look back at FY24

Look at the capex over FY23 and FY24. The capacity has gone up from 12.5K to 32.5K which is 2.7x in April 2024

Now let us look at the guidance for FY25. Revenues of Rs 900-950 crs in FY25 and Rs1250-1300cr in FY26 (up from 596crs in FY24) implying 60% growth in FY25 and 37% growth in FY26 and margins expected too move upto 19-20% (up from 17% margins). People can do that math

Stocks looks like a doubler to me in 2 years.

Disclosure: Invested

5 Likes

Maintains FY25 revenue and margin guidance despite weak 1QFY25

Maintains FY26 revenue guidance

2 Likes
  • Q1 FY’25 consolidated revenue grew 15% year-on-year to INR 172.87 crores
  • Volume growth of 27% year-on-year
  • Exports contributed 61% of revenue
  • EBITDA margins constrained due to underutilization of new Pakhajan facility
  • Negative PAT due to depreciation and interest costs from new facility
  • Successfully commissioned new Pakhajan facility in April 2024, adding 20,000 MT capacity
  • Total capacity now at 32,500 MT
  • Opened subsidiary in USA to expand sales network
  • Expect >90% capacity utilization at Pakhajan by FY’26
  • Targeting 50% utilization at Pakhajan by end of FY’25
  • FY’25 revenue target of INR 900+ crores with 19-20% EBITDA margin
  • FY’26 revenue target of INR 1,200-1,300 crores
  • Expect EBITDA margins to stabilize to previous levels by Q3-Q4 FY’25
  • Huge opportunity for further expansion at Pakhajan site
  • Current Pakhajan capacity only 10% of future optimal capacity
  • Addressable market of INR 5,500 crores for new Pakhajan products
  • Seeing delays in exports due to container availability issues
  • Expect export situation to stabilize by Q3-Q4
  • Working with both new and existing customers for Pakhajan ramp-up
  • Long-term supply agreements expected with customers after trials
  • Debt/EBITDA expected to be close to 3x by end of FY’25
  • No plans for equity dilution through QIP
  • Focus on restricting debt/EBITDA to 2-2.5x range going forward
  • New capacity commissioned but ramp-up impacting near-term profitability
  • Strong volume growth despite pricing pressures
  • Confident of achieving targeted utilization and margins once fully ramped up
  • Significant growth opportunity in addressable markets for new products
  • Focus on debt management while pursuing growth plans
4 Likes

It looks like management is giving agressive guidance just for mcap appreciation.
Q1FY25 sales is 172cr so they need to do sales of 240cr in each remaining quarter.
Also borrowing has been increased to 579cr.
In Q1 they have reported loss and interest cost has been increased from 4cr to 14cr.

Now the whole game is depend on execution by management.

6 Likes

1 Like

yes, mgt has given guidance for 900cr topline
i think they gonna miss the topline

Hi everyone,

I am tracking this business & saw today’s results. Would wait for tomorrow’s earnings call to get more clarity on the below points. However, if any of the member has any visibility of the below points - would love to hear about it

  1. Their results looks decent with volumes increasing 18% YoY. Encouraging sign is GMs expanding to 47% from 35% same quarter last year. My earlier understanding was that their Industrial portion would have increased substantially as that was the higher margin business. However, the product mix seems to be 82:18 (Industrial to Consumer). Hence, factor contributing to such high GMs is important to understand & their sustainability.

  2. Their inventories have increased alot. This has also deteriorated their working capital days to now at ~200 compared to ~100 in FY24. Need to understand if there was any price increase in RMs that the promoter were certain of? Or what is the reason of such high increase in inventories as it is increasing working capital by a wide margin.

  3. ~50% of EBITDA is going into debt payments. Debt / EBITDA being as high as 5x is a strong monitorable for anyone tracking this business.

  4. Management had highlighted that they are seeing some downward trend in prices & that should continue for the next 6-9 months. Has the downward trend in prices effected Q2FY25? I don’t think so - as both volumes growth & revenue growth are almost in line. 2% different give or take.

3 Likes
  • Q2 FY25 revenue: INR 167.35 crores (+17% YoY), driven by a 16% increase in sales volumes.
  • EBITDA margin for Q2: 18.8%, with expectations to remain between 17%-19% in the coming quarters.
  • Export contribution: 66% of total sales.
  • Industrial business: Contributed 82% of revenue.
  • New US subsidiary to become operational in January 2025 to expand market reach.
  • Gross margin improved significantly to 45% in Q2 (from 35% YoY) due to favorable product mix (Industrial segment) and contributions from the Pakhajan facility.
  • Volume growth for Q2: 16% YoY; price reductions impacted overall revenue growth.
  • The chemical sector remains under price pressure, but the bottom level of pricing is expected to stabilize.
  • Pakhajan facility utilization: 15% in Q2; expected to reach 35%-40% in Q3 and 60% by Q4 FY25.
  • Long-term guidance: Pakhajan facility to achieve 90% utilization by FY26.
  • Industrial chemicals remain the primary revenue driver, with expected volume growth of 30%-40%.
    *Continues to gain market share, leveraging a strong product portfolio and approvals pipeline.
  • The lubricant additives market estimated at $10-$12 billion, growing at 3%-4% annually.
  • Export markets, particularly the US and Europe, account for over 70% of industrial segment revenue.
  • Inventory levels increased due to customer trials and future production planning.
  • Working capital cycle currently at 200 days, expected to normalize to 110-115 days by March 2025.
  • Long-term debt repayment starts from FY26, with plans to reduce debt-to-EBITDA to 3x by FY26.
  • Gross margin improvement attributed to product mix optimization within the industrial segment.
  • Pricing pressures impacted revenue despite volume growth, with chemical prices expected to stabilize.
  • New customer approvals for Pakhajan products are progressing, with significant ramp-up expected by Q4 FY25.
  • Cautious due to global chemical sector volatility but confident in maintaining EBITDA margins.
  • Operationalization of the US subsidiary in January 2025 to cater to smaller customers with shorter lead times.
  • Focus on long-term contracts to mitigate pricing volatility.
  • Infrastructure investments (e.g., Pakhajan facility) provide room for future capacity expansions at lower incremental costs. Double the capacity with 200cr investment.
  • Long-term focus on sustainability and competitive positioning in mature markets.
  • Stabilizing raw material and freight costs.
  • Increased demand in industrial chemicals.
  • Global pricing pressures in the chemical sector.
  • Delays in customer approvals impacting capacity ramp-up.
  • Pakhajan facility expansion allows for incremental capacity additions with minimal infrastructure costs (~INR 200-250 crores).
  • Long-term plan to expand capacity post-70% utilization.
  • Export to the US and Europe remains a significant contributor to revenue.
  • Tariff changes in the US may present opportunities, though uncertainty remains.
  • Growth focus on Central and Latin America for diversification.
  • FY25 revenue target unlikely to reach INR 900 crores due to pricing pressures, but volume growth remains strong.
  • FY26 revenue target of INR 1250 crores maintained, with expectations of better price stability and margin improvement.
  • Long-term debt repayment begins in FY26 (~INR 25-30 crores per annum).
  • Future capex will leverage existing infrastructure at Pakhajan to minimize costs and enhance ROCE.
2 Likes

Company is planning to raise 125Cr . EGM is being planned for this.

image

1 Like

Yasho Industries Limited is a leading Indian manufacturer and supplier of specialty and performance chemicals, including food antioxidants, aroma chemicals, rubber chemicals, and lubricant additives. It also manufactures BHA (butylated hydroxy anisole), AP (ascorbyl palmitate) and various complementary antioxidants which are used in edible oils, fried foods, poultry feed, confectionery, and vitamin blends.
Established in 1985, the company has significantly expanded its operations and product offerings over the years. It has 3 manufacturing facilities in Vapi Gujarat with a combined capacity of 12500 MTPA. They acquired a 42 acres land in Dahej for further greenfield expansion which is the new plant at Pakhajan.


Products

Two major verticals - Consumer and Industrial with total 142 products (according to latest ppt)

Product Details
Rubber Chemicals Accelerators / Antioxidants / Co-agents for processing EPDM, SBR, NBR, ECO, Acrylic, NR and more.
Pre-dispersed Rubber Chemicals For dust-free handling and to achieve better Dispersion.
Aroma Chemicals Is a market leader in a supply of Clove oil & its derivatives.
Food Antioxidants Form the company’s core business and Yasho is amongst the leading manufactures of Food Antioxidants in India.
Lubricant Additives Manufactures a range of Additives for Industrial / Automotive Lube & Greases like Antioxidants (Phenolic / Aminic), Molybdenum based Friction Modifiers / Antiwear agents, Dithiocarbamates, Thiadiazoles Corrosion Inhibitor & Extreme pressure additives, Triazole Metal Deactivators
Specialty Chemicals Manufactures various Specialty Chemicals used in different segment of industry such as Electroplating chemicals, Intermediates for API / Bulk Drugs, UPR Resins / Fibre Composites Resins, Thermoplastics Urethanes (Polyurethanes), Printing Inks & Agrochemicals.
  • The Industrial division is the key revenue driver contributing 84% of the revenue while consumer contributes the rest.
  • 4 new products in the pipeline with an addressable market of 5500 crores in Pakhajan.
  • The company is more focused on industrial segment which is a higher margin segment and according to the management, the consumer segment isn’t growing.
  • There products can be further divided into commodity and Value added products (VAP)
    • Commodity: Includes chemical for tire manufacturing. The new plant at Pakhajan focuses on producing high volume commodity type specialty chemicals with average selling price of around 350.
    • VAP: Out of the specialty chemicals for rubber and lubricants which are split in 60-40 ration, about 25-30% are VAP. YALUB and YANTQ are the brands in lubricants and food preservation respectively.

Geography

They have customers in over 50 countries with over 2000 customers. They have offices in India, US, Europe and are expanding in Latin America.

Geography Revenue % share
India 36
US 17
Europe 29
R.O.W. 18
  • Within the Industrial segment, US and Europe account for 70% of the revenue and US is 40% of the revenue in the overall export segments.
  • Central and Latin America are potential markets for future expansion, while the company has already expanded in Asia and middle east.

Clients

  • Over 2000 clients with the top 10 customers contributing approx. 30-35% of the total revenue with all of them being with them for over 5-7 years.
  • Works on long-team contracts with price and volume commitments for a quarter/ 6 months to mitigate price fluctuations and customer cautions.

Raw Material

  • Sources 40% of its RM from sustainable sources
  • Few of the key raw materials include:
    • Hydrophenol is sourced from Europe, the USA, and Japan.
    • Diphenamide is procured from suppliers in the USA, Europe, and China.
    • Amines are obtained both locally in India and through imports from Europe and China.
    • Raw materials for aroma chemicals are imported primarily from Indonesia and Madagascar.

Competition

  • China is a big competitor and due to dumping from China, there is a pricing pressure. Even with China + 1, the customers want chinese prices for non-chinese chemicals
  • Lubrizol in lubricants is a big player and they get competition from established players in Europe

Industry Insights

  • Global Chemical and petrochemical market is expected to reach $300 billion by 2025 with the Indian specialty chemicals industry positioned as a prime catalyst for India’s economic growth and development. It is designated as a sunrise sector by the Ministry of Chemicals and Fertilisers.
  • The lubricant market size is about $10 to $12 billion and the market growth is between 3% to 4%.
  • The Indian specialty chemical market is growing at almost 2x the global.
  • There has been a slowdown in the industry due to destocking and economic weakness in Europe & China.

Subsidiary

Two wholly owned subsidiary, both engage in specialty chemicals.

  • Yasho Industries Europe B.V.:
    • Acquired in 2021, located in Netherlands, provides stocking location in Rotterdam.
  • Yasho Inc.:
    • Acquired in 2023, US, it will serve as a stock point for the company’s US retail customers, it will help increase profit margins by 3-5% by holding stock locally by reducing lead time (Eliminates wait time for 90-120 days)

Growth triggers

  • Rising demand for specialty and performance chemicals, growth in the Indian chemical space.
  • Shifting global supply chain from China due to geopolitical issues (China+1)
  • India’s emergence as a prominent manufacturing hub, PLI schemes and anti dumping duty by the government.

Capex

  • Greenfield capex at Pakhajan, Dahej, Gujarat with capacity of 20k MTPA with cost of 470 crore and is expected to add 550 crores topline at peak utilization and manufacture ~15 products. They have invested in automation, efficiency enhancement at its new facilities which along with inflation and other variables have increased the cost from initial 400 crores.
  • 50% utilization by FY25 and 100% by FY26 and no further expansion until plant reaches 70% utilization.
  • TAM of the products manufactured at the new plant is around 5500 crores.
  • Cost of fund is 8.75% and the management does not plan to reduce borrowings but use the cash flows from the plant to finance future expansion. ln FY25 there is no repayment for the term loan and it will be 45-50 crore in FY26.

Notes

  • Vapi is totally saturated and there is no room left for expansion
  • Topline guidance of 900-950 in FY25 and 1250-1300 in FY26, they expect 30-40% volume growth to achieve it.
  • Guidance of EBITDA margin of 19-20% in FY25 and to maintain debt/EBIDTA of 2-2.5 times. Target working capital cycle within 105 days.
  • There is a volume growth however there is a decline in topline due to pricing pressure which has reduced gross margins.

Disclaimer: Studying, not invested. Any and every feedback is appreciated.

One has to track how the volume growth comes in the coming quarters and how quickly price pressure cools down.

3 Likes

Results for Q3 were not that good and it didn’t achieved their initial guidance of capacity utilization. Further promoters raised some money for paying long term debt and future expansion (now being utilised in working capital maybe kind of signal of some stress in liquidity and balance sheet).
Malabar (Sumeet Nagar) entered must have been one of guys from whom money was raised.

yes, bcoz of this P/E has crossed 100.
and mgt is still optimistic after not meeting initials.

1 Like